Steven Spitalnik, MD [Chair] ('13)
Steven R. Sloan, MD, PhD [Vice Chair] ('13)
Richard J. Benjamin, MD ('15)
Michael P. Busch, MD, PhD ('15)
Terry Gernsheimer, MD (’13)
Yelena Ginzburg, MD ('14)
Andreas Greinacher, MD ('14)
Jeanne Hendrickson, MD ('16)
Hubert Schrezenmeier, MD ('16)
Christopher C. Silliman, MD, PhD ('16)
Connie M. Westhoff, PhD ('14)
The Scientific Committee on Transfusion Medicine identifies and encourages advances in basic and clinical research that can be translated into improving the clinical practice of transfusion medicine. These discoveries concern blood cells (red cells, leukocytes, platelets, hematopoietic progenitor cells, etc.), proteins (e.g. coagulation factors), growth factors (erythropoietin, colony stimulating factors, etc.), regulatory molecules, apheresis methods, and tissue banking.
The focus of this committee will include:
Support for transfusion recipients. The Scientific Committee on Transfusion Medicine supports development, evaluation, and improvement of transfusion therapies for treatment of patients with malignant as well as non-malignant clinical conditions, including hypoproliferative cytopenias and bleeding disorders such as hemophilia, anemia, thrombocytopenia. Areas of importance include thrombotic thrombocytopenia purpura (TTP) and hemolytic uremic syndrome (HUS). Conditions in which transfusion recipients have mounted immune responses to transfused blood products or cells also represent specific areas of importance. These conditions include, but are not limited to, hemophilia complicated by the presence of FVIII or FIX inhibitors, hemolytic disease of the newborn (HLDN), neonatal alloimmune thrombocytopenia (NAIT), drug-induced thrombocytopenia (DIT), and transfusion-related acute lung injury due to neutrophil-specific alloantibodies. Emerging areas: Genomics of blood group antigens; Molecular genetic approaches to blood group antigen typing; Novel recombinant coagulation factors for therapeutic purposes; Coagulopathy associated with massive transfusion; Blood management/Avoidance of transfusion (bloodless surgery); Age of blood and blood storage; Blood substitutes.
Management of patients and donors undergoing apheresis. The Scientific Committee on Transfusion Medicine encourages basic and clinical research to improve the clinical practice of therapeutic apheresis, which is used to manage patients with conditions such as thrombocytosis, polycythemia vera, and sickle cell disease. Also encouraged are efforts to improve the practice of donor apheresis for procurement of cells needed for cellular therapies, which include but are not limited to HLA-matched platelets and mobilized peripheral blood stem cells.Emerging areas: Novel apheresis methods, including photopheresis and other extracorporeal modifications.
Cellular therapeutics. The Scientific Committee on Transfusion Medicine encourages efforts to improve the processes involved in procurement, characterization, and expansion of blood cells for use as cellular therapeutics. Cellular therapies of importance include the uses of autologous and allogeneic hematopoietic stem cells (HSCs) for treatment of hematological and oncological diseases, mesenchymal stem/stromal cells (MSCs) for management of graft vs. host disease, and natural killer (NK) cells, T cells or dendritic cells (DCs) to target tumors and virally-infected cells. Emerging areas: Standardization of protocols for generation of GMP-grade reagents for cellular therapeutics; Genetic modification of blood cells for use in gene therapy; Processing and storage of HSCs and MSCs for damaged organ regeneration (e.g., myocardial injection after MI).
Hemovigilance.The Scientific Committee on Transfusion Medicine encourages efforts to ensure the safety of the blood supply, including optimization of methods for collecting, manufacturing, storing and transfusing blood products, improvement of donor screening and health, and development of new and improved tests for transfusion-transmitted infectious diseases. Emerging areas: Adverse effects of transfusions of red blood cells after prolonged storage.
Donor safety. The Scientific Committee on Transfusion Medicine supports efforts to ensure the safety of blood donors. Emerging areas: Iron overload and iron deficiency in blood donors.
Areas of overlap:
The Scientific Committee on Transfusion Medicine differs from closely-related committees (e.g. Stem Cells and Regenerative Medicine, Transplantation Biology) in that the cell source is typically peripheral blood, placental blood, or a cell that is readily mobilized and released into peripheral blood using pharmacological agents. This typically includes blood cells with no or limited proliferative potential in vivo, as well as various circulating stem cells. Specifically, the Scientific Committee on Transfusion Medicine does not focus on induced pluripotent stem cells or embryonic stem cells, except for the ex vivo generation and expansion of blood cells for transfusion. In addition, unlike the Transplantation Biology Committee, the Scientific Committee on Transfusion Medicine emphasizes the clinical laboratory manipulation and storage of cellular products for subsequent therapeutic purposes, rather than the process of stem cell transplantation itself.
Nonetheless, there is potential overlap with:
Scientific Committee on Iron and Heme:
Iron status of blood donors; intentional or accidental infusion of free hemoglobin
Scientific Committee on Blood Disorders in Childhood:
Pediatric transfusion therapy
Scientific Committee on Stem Cells and Regenerative Medicine:
Hematopoietic stem cell collection and modification; tissue banking
Scientific Committee on Platelets:
Platelet collection and transfusion therapy; thrombopoietic growth factors
Scientific Committee on Hemostasis:
Recombinant coagulation factors; platelet transfusion therapy
Scientific Committee on Hematopoiesis:
Hematopoietic stem cell collection and modification; ex vivo generation and expansion of blood cells for transfusion therapy
Scientific Committee on Transplantation Biology:
Hematopoietic stem cell collection and modification; treatment of graft rejection by therapeutic apheresis and extracorporeal phototherapy; alloimmunization to blood group and histocompatibility antigens
back to top